ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023

Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.

Linda Söderberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.